gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Tafasitamab binds CD19 on B cells and engages CD16A on NK/macrophages via its Fc to trigger ADCC/ADCP against CD19+ cells; CD16A-expressing effector cells are not targeted or killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc region engagement on NK cells mediating ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05615636
disease_id_num_tar_ref
5739
drug_id_num_tar_ref
15598